



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

May 22, 2025

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Dear Sir/ Madam.

Sub: Regulation 30(6) of SEBI (LODR) Regulations, 2015

Please find enclosed herewith the Results Presentation for the Quarter and financial year ended March 31, 2025, for your record.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited


Ananta Narayan Panda
Company Secretary & Compliance Officer

Encl: as above

windlas

Windlas Biotech Limited

Investor Presentation – May 2025



Safe Harbour



This presentation and the accompanying slides (the “Presentation”), which have been prepared by Windlas Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Managing Director's Message



Mr. Hitesh
Windlass

"The Indian Pharmaceutical Market (IPM) registered a YoY growth of 8.4% in FY25, largely driven by price increases with volume growth of 0.4%. We are pleased to report another quarter of strong performance of revenue growth of 20% YoY for FY25 and 18% YoY in Q4FY25.

Our Generic Formulations CDMO vertical continued to benefit from new customer additions and a broader product portfolio. The Trade Generics & Institutional vertical maintained its growth momentum through wider market penetration and institutional engagement. The company continues to work towards the initiatives in the export vertical such as filing of numerous dossiers and entry into newer markets.

Our proactive investments in quality systems, infrastructure, and digital transformation continue to position us strongly with respect to Schedule M compliance. We have begun utilizing Plant-2 extension in Q4 FY25 which gives us the required room for growth in upcoming period. Our Injectable facility has been approved by several large customers and few Injectable products made by us have been commercialized by our CDMO as well as Trade Generics verticals. We continue to augment our manufacturing network through modernization and retrofit of our recently acquired Plant-6 oral solids facility as per plan.

The company achieved its highest-ever earnings per share (EPS) in FY25 (Rs 29.19) post listing. In line with our dividend policy, the company paid Rs 11.5 crores (Rs 5.5 per share) dividend related to FY24 and proposed the dividend of Rs 12.1 crores (Rs 5.8 per share) related to FY25.

Looking ahead, we remain focused on enhancing long-term value for shareholders through diversification of client-base, increasing operational efficiencies, retaining & rewarding of key talent and expansion of dosage forms."

CEO & CFO's Message



**Ms. Komal
Gupta**

"We are pleased to conclude FY25 with strong performance across key metrics:

- *Rs 759 Cr. Revenue, 20.4% YoY growth*
- *9th straight quarter of record revenue, Rs 202.7 Cr. (18.3%YoY growth)*
- *Highest ever EPS of Rs 29.19 post listing*
- *Working Capital days 14*
- *Sustained ROCE & ROE > 20% alongside capacity expansion projects*
- *Strong liquidity Rs 213 Cr.*

We have sustained our operating margins, reflecting our robust financial management despite an increase in depreciation, largely attributable to the Injectables facility and the Plant-2 extension. PAT stood at Rs. 61.0 crore for FY25 and Rs. 16.3 crore for Q4FY25 – as compared to Rs. 58.2 crore and Rs. 17 crore for FY24. EBITDA grew by 20% YoY to Rs. 94.1 crore for FY25, and by 16% YoY to Rs. 25.5 crore for Q4FY25.

India's pharmaceutical industry ranks as the third-largest globally by volume. Our state-of-the-art manufacturing facilities in Dehradun strengthen our ability to deliver high-quality, scalable solutions to meet the evolving demands of the market. Windlas is strategically positioned to capture growth through diversified presence across its core verticals.

In Generic Formulations CDMO vertical we continue to direct our efforts towards sustained client engagement, new client acquisitions, new product launches and higher wallet share from current partners.. This vertical recorded 15% YoY increase in FY25 to Rs. 555.1 crore. For Q4FY25, this vertical generated Rs. 147.2 crore in revenue, witnessing 15% YoY growth.

Trade Generics and Institutional vertical is driven by portfolio expansion, broader distribution and institutional network, also supported by government driven initiatives. Our Trade Generics and Institutional vertical continued its growth momentum in FY25, with revenue surged to Rs. 172.1 crore, marking a 41% YoY increase. For Q4FY25, revenue increased to Rs. 45.5 crore, registering 31% growth YoY.

Exports vertical reported revenue of Rs. 32.6 crore in FY25, a 19% increase YoY, with Q4FY25 showing a revenue of Rs. 10.0 crore reflecting 12% growth YoY.

In conclusion, FY25 has been a year of meaningful progress for Windlas—anchored by consistent growth, resilient margins, and strategic execution. These results underscore the strength of our business fundamentals and the clarity of our vision. As we look ahead, we remain confident in our ability to seize emerging opportunities and deliver enduring value to all our stakeholders"



Financial Performance Highlights



Key Highlights: FY25



01

Revenue 760 Cr.
YoY growth 20%

02

9th straight quarter of
record revenue 203 Cr

03

EBITDA 94 Cr.
YoY growth 20%

04

Highest ever EPS
post listing 29.19

05

Cash generated from
operations 68.2 Cr.

06

Working Capital days 14

07

ROCE* - 25%
ROE* - 23%

08

Strong Liquidity 213 Cr.
(Capex FY25 72 Cr.)

*For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period


Annual Performance Highlights

windlas

Rs. Crores


Consolidated

Revenue




**Clocked in highest
ever annual Revenue
& EBITDA**

EBITDA & EBITDA Margin (%)




Vertical Revenue


Generic Formulations CDMO



Trade Generics & Institutional



Exports




Quarterly Performance Highlights

windlas

Rs. Crores


Consolidated

Revenue




9th straight
quarter of record
revenue 203 Cr

EBITDA & EBITDA Margin (%)




Vertical Revenue


Generic Formulations CDMO



Trade Generics & Institutional




Exports




Vertical Break-up

FY24




CDMO Trade Generics & OTC Exports

FY25




CDMO Trade Generics & OTC Exports

Q3FY25




CDMO
Trade Generics & OTC
Exports

Q4FY24



CDMO
Trade Generics & OTC
Exports

Q4FY25



CDMO
Trade Generics & OTC
Exports

Consolidated Profit & Loss Statement – Q4 & FY25





Particulars (Rs. Crores)	FY25	FY24	YoY%	Q4FY25	Q4FY24	YoY%
Net Revenue from Operations	759.9	631.0	20.4%	202.7	171.3	18.3%
COGS	471.9	396.2		125.2	107.2	
Gross Profit	288.0	234.8	22.7%	77.5	64.1	20.9%
Gross Margin (%)	37.9%	37.2%	69bps	38.2%	37.4%	80bps
Employee Expenses	122.9	87.5		31.9	22.8	
Other Expenses	71.0	69.2		20.0	19.3	
EBITDA	94.1	78.2	20.4%	25.5	22.0	16.3%
EBITDA Margin (%)	12.4%	12.4%	0bps	12.6%	12.8%	-22bps
Other Income	18.0	13.5		4.9	4.4	
Finance Costs	4.4	1.1		1.3	0.3	
Depreciation*	28.0	13.4		8.3	3.5	
Reported PBT*	79.8	77.1	3.5%	20.8	22.6	-7.8%
Taxes	18.8	19.0		4.5	5.6	
Reported PAT*	61.0	58.2	4.8%	16.3	17.0	-4.0%

*Almost all incremental depreciation is attributable to new facilities (Injectable & PI-2 extension).

Rewarding Shareholders

- The highest ever earnings per share (EPS) post listing stood at Rs. 29.19 in FY25.
- Dividend:
 - In line with our policy, Company proposed to pay the dividend of Rs 12.1 Cr (Rs 5.8 per share) to its shareholders for FY25 and paid dividend of Rs 11.5 Cr (Rs 5.5 per share) related to FY24.
 - According to our company policy, we aim to maintain a Dividend Payout Ratio as near as possible to 20% of our consolidated profit after tax, subject to -
 - Company's need for Capital for its growth plan
 - Positive Cash Flow



*Adjusted for exceptional items in FY21 (Negative Impact of Rs. 22 Crs)


**Proposed dividend for the financial year ended March 31, 2025, which shall be payable subject to the approval of shareholders at the ensuing Annual General Meeting ("AGM") of the Company



Company Overview



Windlas Biotech at Glance




PBT and PAT include incremental depreciation majorly attributable to Injectable facility.

*from the State Drug Licensing Authority, Drug Controlling and Licensing Authority (Manufacturing), Garhwal Mandal, Uttarakhand

** For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period

Windlas Biotech's Presence in Pharma Value Chain



- ➡ *Windlas is present in all segments of Generics Value chain*
- ➡ *#Windlas focus is on formulation, development, manufacturing and marketing*
- ➡ *We invest in creating our own formulation technology for our products. Almost 100% of our CDMO supplies are based on products where we own the entire IP from initiation to regulatory permission.*

Journey So Far...



- Commenced operations at Dehradun Plant – I and initiated commercial production

- Commenced operations at Dehradun Plant – IV
Revenues crossed INR 100 Crores for FY2010

- Received first USFDA inspection clearance
- Revenues crossed ₹200 Crores for the FY 2013-14
- Commenced operations at Plant – II
- Investment of ₹75 Crores from Tano India Private Equity Fund II

- Revenues crossed ₹300 Crores for the FY 2016-17
- Launched first product in the United States from the Dehradun Plant – IV
- Commenced operations at Dehradun Plant – III
- Divestment of Windlas Healthcare to Cadila Healthcare

2001

2010

2014-15

2018

2025

2023-24

2021-22

2019-20

- Revenues crossed ₹750 Crores for the FY25
- Injectable facility GMP certified
- Completed Plant 2 extension
- Initiated PI-6 capex for OSD capacity expansion

- Plant-IV approved by SAPHRA(South Africa) and EU-GMP(Europe)
- Commissioned Plant-V Injectable facility

- Got listed on Exchanges in August 2021
- Capacity of Capsules/ Tablets increased from 5 Bn+ as of Mar 31,2020 to 7 Bn+ as of March 31, 2022

- Invested ₹89 Mn in building Plant and Machinery
- Acquired the erstwhile associate – Windlas Healthcare(Now Plant-IV)

Strong Board of Directors...



Ashok Kumar Windlass
Whole Time Director

- **Ex Chairman of Confederation of Indian Industries**, Uttarakhand State Council,
- **Established Windlas Biotech in 2001.**
- Led Windlas Biotech as MD till 2020



Hitesh Windlass
Managing Director

- **23+ years of experience in field of management**
- Bachelor's degree from the **IIT-BHU, MS in Material Science & Engr. from Georgia Institute of Technology and MBA from the Booth School of Business, University of Chicago**
- Leads the company since 2008



Manoj Kumar Windlass
Jt. Managing Director

- **Co-founded Windlas Biotech in 2001**
- Deeply engaged in **managing client relations, and product portfolio expansion**
- Plays a significant role in driving the product portfolio decisions and overall commercial operations including business development, supply chain and procurement
- He is a BBA graduate from George State University Atlanta



Pawan Sharma
Executive Director

- **24+ years** of experience in the pharmaceutical industry, he has a Bachelor's degree in Law from the Hemwati
- Nandan Bahuguna Garhwal University, Srinagar (Garhwal)



Prachi Jain Windlass
Non-Executive Director

- **22+ years** of experience.
- Bachelor's degree in technology from the IIT, Delhi, Master's degree in science from University of Southern California, and an MBA from University of Chicago.
- Currently associated with Michael & Susan Dell Foundation India and previously with Boston Consulting Group



Gaurav Gulati
Independent Non-Executive Director

- Bachelor's degree in Science (computer science) from the University of Illinois. MBA from Booth School of Business.



Vivek Dhariwal
Chairman and Independent Director

- **24+ years** of experience in manufacturing and supply operations.
- Previously associated with ICI India Ltd, Baxter India Private Ltd, and Pfizer Ltd.
- Bachelor's degree from IIT-B & Master's degree in science from University of Kentucky



Srinivasan Venkatraman
Independent Non-Executive Director

- Fellow member of the Institute of Chartered Accountants of India.
- Previously associated with Wealth Tree Advisors, Hines, Aon Global Insurance Services, and Lovelock & Lewes

...Coupled with Proficient Management Team



Ms. Komal Gupta, *CEO & CFO*

- Experience – 20+ Years;
- Educational Qualification - CA, CS & CWA
- Working with Windlas since 2015
- Previously worked with DSM Group and Anand Automotives Systems Ltd.



Mr. Ananta Narayan Panda, *Company Secretary and Compliance Officer*

- Experience - 24+ Years;
- Previously worked with GMR Airports Limited, Spice Smart Solutions Limited



Mr. Om Prakash Sule, *Site Quality Head*

- Experience - 28+ Years;
- Previously worked with Piramal Enterprises Limited and Mankind Pharma Limited.



Mr. Mohammed Aslam, *President – Sales and Marketing*

- Experience - 45+ Years;
 - Educational Qualification - Graduate in Science (Biology & Chemistry)
- Previously worked with Pharmed -Bracco, Modi-Mundi Pharma, a Swiss MNC and Dalmia Industries Limited


Vertical Overview

Generic Formulations CDMO



- Generic Formulations CDMO vertical focused on providing products & services across- a diverse range of pharmaceutical & nutraceutical generic products.
- 'Marketeers' equally responsible for quality of the drug product in eyes of regulator
- New schedule M implemented in October 2021 – many small manufacturers may become unviable
- Such products are sold to Indian or foreign Pharma MNCs who market products under their own brand names.
- Intellectual Property Rights of 99% of products sold owned by Windlas.

Contribution as a % of Total Revenue from Operations




Trade Generics & Institutional



- This vertical consists of Trade Generics which includes products sold to various institutions.
- These products are Drugs for which Patents have been expired and are typically used as a substitute to branded expensive Generic medicines.
- Generally sold to the Distributors & not Medical representatives.

Contribution as a % of Total Revenue from Operations




Exports



- Export vertical is engaged in identifying high growth opportunities in Semi regulated international markets & selected regulated markets.
- The motive is to Develop & Register product applications in order to obtain marketing authorizations for medicines & health supplements.
- Subsequently such products are sold to Pharmaceutical Companies & Pharmacies in the respective markets.

Contribution as a % of Total Revenue from Operations



Generic Formulations CDMO Business Highlights



No. Of Customers

757

No. of Brand Catered (Brand ownership with customers)

5,582

Products

Fixed dosage, Fixed dosage plus modified release, Customized generics, chewable/ dispersible and plain oral solids

Revenue Mix (% of FY25)

73%

Amongst the leading Domestic Generic Formulations CDMO in India

Intellectual Property Rights of 99% of products sold owned by Windlas


Well Diversified Product Portfolio



Windlas provides Generic Formulations CDMO products & services ranging from product discovery, product development, licensing and commercial manufacturing of complex generic products in compliance with current GMP

Company's product portfolio predominantly overlaps with Fast Growing Chronic vertical and High Margin Complex Generic Vertical:

Portfolio Bifurcation as % of Total Revenue from Operations FY25




■ Chronic & Sub-Chronic ■ Complex Generics
■ Acute ■ Conventional Products


(i) chronic and sub-chronic, such as, anti-diabetic, cardiovascular, neuropsychiatry, respiratory health and nutraceuticals ; and (ii) acute, such as, gastroenterology, vitamins, minerals and supplements ("VMS"), analgesic, dermatological and cough/ cold

Generic Formulations CDMO Revenue grew with a CAGR of 14%

INR Crores



No. of Generic Formulations CDMO Products Catered every year



Value chain of End-to-end Services



Product Discovery & Development



Licensing



Contract Manufacturing

Large Marquee Customer Base

windlas

✓ Streamlined Client Acquisition Process




✓ Key Factors that lead to Expansion of Customer base

- ➡ Audits by several MNC & Domestic Customers over the years
- ➡ Product Excellence : dosage innovation, developing complex generic products
- ➡ Manufacturing Excellence : track record, responsiveness, quality & technical standards, turnaround times
- ➡ Planned capital expenditure: Invested in specialized products and services and equipment and dedicated infrastructure

✓ Key Factors that lead to Expansion of Customer base



- Quality, Quantity and specifications for the products
- Company is responsible for the procurement of raw materials and packaging materials
- Provide the proper pricing & supply terms



Key Highlights




We have consistently maintained strong, **exclusive & Long-Standing relationships** with the leading Indian Pharmaceutical companies.




Provided Generic Formulations CDMO Products and Services to **7 of the top 10 (15 of the top 20)** Indian Formulations pharmaceutical companies.

De-Risking the Customer Concentration


Long-term nature of the relationships help in pre-plan the Capex and eventually help in achieving sustainable growth and profitability



Continuously reducing highest customer's contribution



Lowering client concentration risk



Domestic Trade Generics & Institutional Business Overview **windlas**



Brand Ownership is with Windlas

Company's Brand Names

Products

Focus on Respiratory, Anti-diabetic, Gastroentology & other chronic + sub chronic TA's

Revenue Mix (% of FY25)

23%

No. of Brands

400

Leveraging Trade Generics & Institutional Market Opportunity **windlas**

Highlights

Rs. 172 Crores
Trade Generics & Institutional SBV
revenue (FY25)

Distributed through 1,095
Stockists & Distributors spread across
29 states (FY25)

Sold directly to the distributor and not
marketed through Medical
representatives.

Also includes institutional sales.

Key Drivers

Low costs compared to branded
generics


Similar quality to branded generics but
are sold at relatively lower prices

People in rural areas who are less
privileged to access the healthcare
facilities


Government push for schemes such as
Jan Aushadhi Yojana, encouraging
traded generics use

Fastest Growing SBV in the last three years chart

INR Crores



With number of Brands on growing at a healthy pace



Export Business Overview



No. Of Customers

Focused on Emerging & Semi-Regulated Markets

Brand Used

Own Brands and End Customer Brands

Products

Exported 80 Products during FY25 which includes Generic Medicines & Health Supplements

Revenue Mix: 4% of FY25 Revenue from Operations

Exports SBV: INR of 33 crore as of FY25.

Geographic Reach



Robust R&D Capabilities



Robust R&D capabilities help in Customize and Market Complex; Generic Products to Customers and differentiate from Competition

R&D Key Highlights

DSIR approved
state of the art R&D
laboratory & pilot
scaled equipments

Fully staffed
formulation and
analytical development,
medical affairs and
regulatory teams




Focus on low cost
First-to-launch
generic products

Significant
Experience in
developing
**Multi-Drug
Products**

Consistent in R&D Expenditure

INR Crores



Leading to New Innovations

Medicated chewing gum (multi-vitamin)

Chocolate flavored chewable tablets


Dispersible tablets

Sustained release products


Novel Formulations of Existing Molecules

Robust Growth in Complex Generics

No. of Variations in Complex Generics



**Leading to Significant increase in Revenue from High Margin
Complex Generics:**



Competencies in Manufacturing Facilities



Efficiency & Effectiveness in Regulatory & Quality Compliance act as solid Entry Barriers



Dehradun Plant 1 commenced operations in **2001**



Dehradun Plant 2 commenced operations in **2014**



Dehradun Plant 3 commenced operations in **2018**



Dehradun Plant 4 commenced operations in **2009**




Dehradun Plant 5 commenced operations in **2024**

Total Installed operating capacity per annum


Categories	FY24	FY25
Tablets & Capsules	7,322 Mn	8,522 Mn
Pouch & Sachet	54 Mn Packs	54 Mn Packs

Capacity Utilization % for FY24 & FY25



Plant wise operating capacity as of 31st March FY25

**Capacity in Mn in terms of per annum; excluding injectables*



Key Highlights

Gross block of Fixed Assets
INR 352.04 Crores
As of Mar 2025

Successful Audits
done by MNCs & Large Domestic Customers

Capex for FY25 stands at
Rs. 72.2 Crores

INR 246.5 Crores
Invested in building PPE & Other
**Intangible Assets of Last 5 years

All 5 Plants are WHO-GMP compliant


Total 177 Employees in Quality Control
As of FY25

***Intangible Assets excluding CWIP/ROU/Intangible under development)*

Strategies & Way Forward...

Strategic Investments/ Acquisitions

- **Leading in Generic Formulations CDMO status benefits the company from the Industry consolidation trend** in an already highly fragmented market with few organized and large unorganized players



Innovation & Product Development

- Continue to focus on **expanding the product development and manufacturing capabilities in complex generic** products and **take advantage of the near-term patent expiry of key molecules**




Historical Financial Snapshot




Financial Snapshot

windlas


Revenue (Rs. Crores)




EBITDA (Rs. Crores)




PAT (Rs. Crores)




EBITDA (In %)



PAT (In %)



EPS



*Adjusted for exceptional items in FY21 (Negative Impact of Rs. 22 Crs)


** PAT include incremental depreciation majorly attributable to Injectable facility

Financial Snapshot


windlas

Consolidated


Asset Turnover Ratio




Net Worth (Rs. Crores)




Net Debt to Equity (x)




ROCE (In %)



ROE (In %)



Net Debt to EBITDA (x)



Note:

**Adjusted for exceptional items in FY21 (Negative Impact of Rs. 22 Crs)

1. All ratios calculated considering capex for Injectables (Plant-5), Plant-2 extension and Plant-6 (upcoming). For FY25 two bars have been shown, one considering complete capex and second *excluding CWIP of Plant-6.
2. For ROCE & ROE, Capital Employed & Equity at the end of period after removing cash/bank & mutual fund balances at the end of period

Consolidated Profit & Loss Statement



Consolidated

Particulars (Rs. Crores)	FY25	FY24	FY23	FY22	FY21	FY20
Net Revenue from Operations	759.9	631.0	513.1	465.9	427.6	328.9
COGS	471.9	396.2	325.4	302.8	274.4	211.6
Gross Profit	288.0	234.8	187.6	163.1	153.2	117.3
Gross Margin (%)	37.9%	37.2%	36.6%	35.0%	35.8%	35.7%
Employee Expenses	122.9	87.5	70.3	63.4	58.3	43.6
Other Expenses	71.0	69.2	57.1	47.3	40.4	39.7
EBITDA	94.1	78.2	60.2	52.4	54.5	34.0
EBITDA Margin (%)	12.4%	12.4%	11.7%	11.3%	12.7%	10.3%
Other Income	18.0	13.5	10.0	6.7	3.1	2.5
Finance Costs	4.4	1.1	0.8	1.4	1.3	2.5
Depreciation	28.0*	13.4	12.4	12.1	13.0	9.3
PBT before exceptional items	79.8*	77.1	57.0	45.6	43.4	24.7
Taxes	18.8	19.0	14.4	7.5	6.2	8.5
Reported PAT	61.0*	58.2	42.6	38.1	15.6	16.2
Exceptional (Loss)/Gain	0.0	0.0	0.0	0.0	(21.6)	0.0
Tax benefit due to merger with Windlas Healthcare	0.0	0.0	0.0	0.0	8.3	0.0
Adjusted PAT	61.0	58.2	42.6	38.1	28.8	16.2
Adjusted PAT Margin (%)	8.0%	9.2%	8.3%	8.2%	6.7%	4.9%
Adjusted Earnings Per Share (EPS)	29.19	27.97	19.70	18.58	15.99	8.90

* PBT and PAT include incremental depreciation majorly attributable to Injectable facility

Note: EPS on closing number of shares for FY23 and FY24 comes to 29.19 and 27.97 respectively.

Consolidated Balance Sheet



Consolidated

Assets (Rs. Crores)	FY25	FY24	FY23	FY22	FY21	FY20
Non Current assets						
Property, Plant and Equipment	195.5	169.5	102.6	88.4	92.5	66.1
Capital work in progress	3.2	5.7	13.8	7.6	0.0	0.0
Right to use assets	23.2	5.1	6.3	2.3	3.0	3.6
Other Intangible assets	4.7	4.5	0.5	0.5	0.0	0.0
Intangible assets under devlp.	2.1	0.0	1.0	0.4	0.5	0.6
Financial Assets						
(i) Investments	0.0	0.0	0.0	0.0	0.0	94.0
(ii) Other Financial Assets	3.3	4.3	7.6	5.2	3.0	2.2
Deferred Tax Assets (net)	0.3	0.6	2.0	2.0	0.0	0.7
Other non-current assets	2.1	5.3	41.6	3.0	2.9	3.3
Total Non Current Assets	234.3	194.9	175.4	109.4	101.8	170.5
Current Assets						
Inventories	81.4	62.2	74.7	58.7	41.5	49.3
Financial Assets						
(i) Investments	223.4	173.4	106.5	64.8	23.1	22.3
(ii) Trade receivables	166.9	136.3	116.9	110.8	79.4	63.9
(iii) Cash and Bank Balances	0.4	5.3	3.7	0.6	15.9	18.1
(iv) Bank Balances other than cash & cash equivalents	16.5	25.7	21.8	113.2	15.2	0.3
(v) Other Financial Assets	1.0	1.5	1.5	4.2	0.4	0.1
Current Tax Assets(Net)	3.3	0.7	0.0	4.1	4.0	0.9
Other current assets	33.3	26.2	28.5	25.3	14.8	13.1
Total Current Assets	526.1	431.3	353.5	381.7	194.3	168.0
Total Assets	760.4	626.2	528.9	491.0	296.1	338.5

Equities & Liabilities (Rs. Crores)	FY25	FY24	FY23	FY22	FY21	FY20
Equity						
Equity Share capital	10.5	10.4	10.5	10.9	6.4	6.4
Other Equity	495.3	439.5	391.8	383.9	192.7	203.2
Total Equity	505.8	449.9	402.3	394.8	199.1	209.7
Financial liabilities						
(i) Borrowings	0.0	0.0	0.1	0.4	0.8	1.2
(ii) Other Financial liabilities	0.1	0.2	0.3	0.2	0.2	0.1
(iii) Lease Liability	2.3	2.0	3.0	0.0	0.5	1.0
Deferred tax liabilities (Net)	0.0	0.0	0.0	0.0	0.7	0.0
Provisions	2.9	2.3	2.0	1.6	1.4	1.2
Total Non Current Liabilities	4.2	4.5	5.5	2.2	3.6	3.5
Financial liabilities						
(i) Borrowings	27.1	0.1	0.3	5.7	30.5	20.9
(ii) Trade Payables	167.2	131.5	87.7	63.2	39.9	83.6
(iii) Other financial liabilities	37.5	33.2	26.4	22.7	19.4	1.5
(iv) Lease Liability	3.2	1.5	1.5	0.5	0.5	18.9
Provisions	1.6	0.7	0.4	0.3	0.3	0.0
Current tax liabilities (Net)	0.0	0.6	0.5	0.0	0.0	0.0
Other current liabilities	12.8	4.7	4.1	1.5	2.7	0.4
Total Current Liabilities	249.4	171.8	121.2	94.0	93.4	125.3
Total Equity and Liabilities	760.4	626.2	528.9	491.0	296.1	338.5

Consolidated Cash Flow



Consolidated

Particulars (Rs. Crores)	FY25	FY24	FY23	FY22	FY21	FY20
Net Profit before Tax and Extraordinary items	79.8	77.1	57.0	45.6	21.7	24.7
Adjustments for: Non Cash Items / Other Investment or Financial Items	18.4	6.6	7.3	10.0	36.3	17.3
Operating profit before working capital changes	98.2	83.7	64.4	55.6	58.0	42.0
Changes in working capital	-9.1	44.0	6.3	-37.6	40.0	3.6
Cash generated from Operations	89.1	127.6	70.7	18.0	18.0	38.4
Direct taxes paid (net of refund)	-20.9	-18.6	-9.7	8.9	6.5	13.4
Net Cash from Operating Activities	68.2	109.0	61.0	9.1	11.5	25.0
Net Cash from Investing Activities	-74.1	-92.1	-14.1	-154.6	-20.2	-14.3
Net Cash from Financing Activities	1.0	-15.3	-43.7	130.1	0.8	-5.4
Net Decrease/Increase in Cash and Cash equivalents	-4.9	1.6	3.1	-15.4	-8.0	5.2
Add: Cash & Cash equivalents at the beginning of the period	5.3	3.7	0.6	15.9	23.9	12.9
Cash & Cash equivalents at the end of the period	0.4	5.3	3.7	0.6	15.9	18.1

Contact Us



Company:



CIN: 74899UR2001PLC033407

Ms. Komal Gupta

Email: komal@windlasbiotech.com

Contact no.: +91 124 2821034

www.windlas.com

Investor Relations Advisor:



CIN: U74140MH2010PTC204285

Mr. Parin Narichania / Ms. Drashti Shah

E: parin.n@sgapl.net / drashti.shah@sgapl.net

T: +91 9930025733 / +91 8767224443

www.sgapl.net